Thiazolidinediones: Antidiabetic drugs with cardiovascular effects

Hellenic Journal of Cardiology

Volumn 47, Issue 6, 2006, Pages 352-360

  Pastromas, Socrates ^a   Koulouris, Spyridon ^a,b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Atherosclerosis; Diabetes mellitus; Endothelial function; Insulin resistance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LIGAND BINDING; LIPID METABOLISM; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; WEIGHT GAIN; BIOLOGICAL MODEL; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY;

ATHEROSCLEROSIS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; MODELS, BIOLOGICAL; THIAZOLIDINEDIONES;

EID: 34247176346     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
2. Schernthaner G: Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 1996; 31 (Suppl): S3-13.
3. Haffner SM, Lehto S, Rönnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
4. Lehmann JM, Moore LB, Smith-Oliver TA, et al: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
5. Einhorn D, Kipnes M, Glazer NB, et al: Durability of glycemic control with pioglitazone in long-term combination and monotherapy. Diabetes 2001; 50 (Suppl): A111.
6. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al: Non-hypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71.
7. AVANDIA© (rosiglitazone maleate): Prescribing information, 2005, GlaxoSmithKline.
8. ACTOS® (pioglitazone hydrochloride): Prescribing information, Takeda Pharmaceuticals America, Inc.
9. Scheen AJ: Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27: 305-313.
10. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
11. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435.
12. Chawla A, Repa JJ, Evans RM, et al: Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-1870.
13. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
14. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
15. Luquet S, Lopez-Soriano J, Holst D, et al: Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 2004; 86: 833-837.
16. Marx N, Duez H, Fruchart JC, et al: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94: 1168-1178.
17. Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
18. Davidson MB: Clinical implications of insulin resistance syndromes. Am J Med 1995; 99: 420-426.
19. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
20. Miyazaki Y, Glass L, Triplitt C, et al: Effect of rosiglitazone on glucose and nonesterified fatty acid metabolism in Type 2 diabetic patients. Diabetologia 2001; 44: 2210-2219.
21. Kim YB, Ciaraldi TP, Kong A, et al: Troglitazone but not metformin restores insulin stimulated phosphoinositide 3-kinase activity and increases p110[β] protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002; 51: 443-448.
22. Miyazaki Y, Mahankali A, Matsuda M, et al: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
23. Juhl CB, Hollingdal M, P_rksen N, et al: Influence of rosiglitazone treatment on β-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003; 88: 3794-3800.
24. Yki-Järvinen H: Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
25. Adams M, Montague CT, Prins JB, et al: Activators of peroxisome proliferator-activated receptor have depot-specific effects on human preadipocyte differentiation. J Clin Invest. 1997; 100: 3149-3153.
26. DeFronzo R: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
27. Khan MA, St: Peter JV, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708-711.
28. Brunzell J, Cohen BR, Kreider M: Rosiglitazone favourably affects LDL-C and HDL-C heterogeneity in type 2 diabetes [abstract]. Diabetes 2001; 50(Suppl 2): A141.
29. Winkler K, Friedrich I, Nauck M, Wieland H, Maerz W: Pioglitazone reduces dense LDL-particles in patients with type-2 diabetes. Diabetes 2001; 50(Suppl 2): A147 (abstract).
30. Chait A, Brazg RL, Tribble DL, et al: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B Am J Med 1993; 94: 350-356.
31. Mehta JL, Hu B, Chen J, et al: Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 2003; 23: 2203-2208.
32. Lewin AJ, Kipnes MS, Meneghini LF, et al: Simvastatin/Thiazolidinedione Study Group: Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2004; 26: 379-389.
33. van Wijk JPH, de Koning EJP, Martens EP, Rabelink TJ: Thiazolidinediones and Blood Lipids in Type 2 Diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-1749.
34. Saleh YM, Mudaliar SR, Henry RR: Metabolic and vascular effects of the thiazolidinedione troglitazone. Diabetes Rev 7: 55-76, 1999.
35. Hiraga T, Kobayashi T, Okubo M, et al: Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995; 18: 241-244.
36. Haffner SM, Morales PA, Stern MP, et al: Lp(a) concentrations in NIDDM Diabetes 1992; 41: 1267-1272.
37. Nagai Y, Abe T, Nomura G: Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients? Diabetes Care 2001; 24: 408-409.
38. Ovalle F, Bell DS: Troglitazone's effect on lipoprotein(a) levels. Diabetes Care 1999; 22: 859-860.
39. Ko SH, Song KH, Ahn YB, et al: The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. Metabolism 2003; 52: 731-734.
40. Sarafidis PA, Lasaridis AN, Nilsson PM, et al: The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005; 54: 1236-1242.
41. Buchanan TA, Meehan WP, Jeng YY, et al: Blood pressure lowering by pioglitazone: Evidence for a direct vascular effect. J Clin Invest 1995; 96: 354-360.
42. Imano E, Kanda T, Nakatani Y, et al: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-2139.
43. Rosenstock J, Raskin P: Hypertension in diabetes mellitus. Cardiol Clin 1988; 6: 547-560.
44. Diep QN, El Mabrouk M, Cohn JS, et al: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-2302.
45. Kaufman LN, Peterson MM, DeGrange LM: Pioglitazone attenuates diet induced hypertension in rats. Metabolism 1995; 44: 1105-1109.
46. Kawasaki J, Hirano K, Nishimura J, et al: Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 1998; 98: 2446-2452.
47. Song J, Walsh MF, Igwe R, et al: Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca+2 currents and not endothelial nitric oxide production. Diabetes 1997; 46: 659-664.
48. Sarafidis PA, Lasaridis AN, Nilsson PM, et al: Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004; 22: 1673-1674.
49. Mattock MB, Morrish NJ, Viberti GC, et al: Prospective study of microalbuminuria as a predictor of mortality in NIDDM Diabetes 1992; 41: 736-741.
50. Erdmann E: Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. Int J Cardiol 2006; 107: 147-153.
51. Pistrosch F, Herbrig K, Kindel B, et al: Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54: 2206-2211.
52. Goetze S, Xi XP, Kawano H, et al: PPAR-gamma ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999; 33: 798-806.
53. Pasceri V, Wu HD, Willerson JT, et al: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-238.
54. Calnek DS, Mazzella L, Roser S, et al: Peroxisome proliferator-activated receptor-gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57.
55. Delerive P, Martin-Nizard F, Chinetti G, et al: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 2003; 85: 394-402.
56. Marx N, Schönbeck U, Lazar MA, et al: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-1103.
57. van Wijk JPH, Rabelink TJ: Impact of thiazolidinedione therapy on atherogenesis. Curr Atheroscler Rep 2005; 7: 369-374.
58. Kai H, Ikeda H, Yasukawa H, et al: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-372.
59. Steinberg J, Fink G, Picone A, et al: Evidence of increased matrix metalloproteinase-9 concentration in patients following cardiopulmonary bypass. J Extra Corpor Technol 2001; 33: 218-222.
60. Jokl R, Colwell JA: Arterial thrombosis and atherosclerosis in diabetes. Diabetes Reviews 1997; 5: 316.
61. Sobel BE: Coronary artery disease and fibrinolysis: from the blood to the vessel wall. Thromb Haemost 1999; 82(Suppl 1): 8-13.
62. Nordt TK, Peter K, Bode C, et al: Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab 2000; 85: 1563-1568.
63. Hsueh WA, Law RE: PPAR γ and atherosclerosis. Effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001; 21: 1891-1895.
64. Haffner SM, Greenberg AS, Weston WM, et al: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
65. Marx N, Froehlich J, Siam L, et al: Antidiabetic PPAR γ -activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288.
66. Raskin P, Rappaport EB, Cole ST, et al: Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-284.
67. Marx N, Imhof A, Froehlich J, et al: Effect of rosiglitazone treatment on soluble CD40L in type-2 diabetic patients with coronary artery disease. Circulation 2003; 107: 1954-1957.
68. Pistrosch F, Passauer J, Fischer S, et al: In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-490.
69. Sidhu JS, Cowan D, Kaski JC: Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 2004; 94: 151-156.
70. Wang TD, Chen WJ, Lin JW, et al: Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004; 93: 362-365.
71. Satoh N, Ogawa Y, Usui T, et al: Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499.
72. Bots ML, Hoes AW, Koudstaal PJ, et al: Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96: 1432-1437.
73. Sidhu JS, Kaposzta Z, Markus HS, et al: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-934.
74. Koshiyama H, Shimono D, Kuwamura N, et al: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endo Metab 2001; 86: 3452-3456.
75. Schofer J, Schluter M, Rau T, et al: Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol 2000; 35: 1554-1559.
76. Marx N, Wohrle J, Nusser T, et al: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005; 112: 2792-2798.
77. Takagi T, Yamamuro A, Tamita K, et al: Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study. J Cardiol 2005; 45: 139-147.
78. Choi D, Kim SK, Choi SH, et al: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-2660.
79. Osman A, Otero J, Brizolara A, et al: Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 2004; 147: E23.
80. Dormandy JA, Charbonnel B, Eckland DJ, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
81. Home PD, Pocock SJ, Beck-Nielsen H, et al: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48: 1726-1735.
82. Kelly IE, Han TS, Walsh K, et al: Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293. Erratum in: Diabetes Care 1999; 22: 536.
83. Nakamura T, Funahashi T, Yamashita S, et al: Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation: double-blind placebo-controlled trial. Diabetes Res Clin Pract 2001; 54: 181-190.
84. Hosokawa M, Tsukada H, Fukuda K, et al: Troglitazone inhibits bicarbonate secretion in rat and human duodenum. J Pharmacol Exp Ther 1999; 290: 1080-1084.
85. Nesto RW, Bell D, Bonow R, et al: Thiazolidinedione use, fluid retention, and congestive heart failure. Circulation 2003; 108: 2941-2948.
86. Shimoyama M, Ogino K, Tanaka Y, et al: Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999; 48: 609-615.
87. Ghazzi MN, Perez JE, Antonucci TK, et al: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46: 433-439.
88. Schneider RL, Shaffer SJ: Long-term echocardiographic assessment in patients with type 2 diabetes mellitus treated with pioglitazone. Diabetes 2000; 49(Suppl 1): A124.
89. Yue TL, Chen J, Bao W: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-2594.
90. Shiomi T, Tsutsui H, Hayashidani S, et al: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126 3132.
91. Thomas ML, Lloyd SJ: Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001; 35: 123-124.
92. Hirsch IB, Kelly J, Cooper S: Pulmonary edema associated with troglitazone therapy. Arch Intern Med 1999; 159: 1811.
93. Tang WH, Francis GS, Hoogwerf BJ, et al: Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003; 41: 1394-1398.